| Citation: |
LUO Wen, ZHANG Ke, LIU Haijun. Application of serum annexin A3 combined with hypoxia-inducible factor-1α in the prediction of platinum resistance in colorectal cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(5): 67-71. DOI: 10.7619/jcmp.20223174
|
To investigate the relationships between the expression of peripheral blood annexin A3 (ANXA3), hypoxia-inducible factor-1α (HIF-1α) and platinum resistance in colorectal cancer.
Clinical data of 122 patients with colorectal cancer treated with platinum-based chemotherapy were retrospectively analyzed. Drug resistance was evaluated after 6 cycles of chemotherapy, and patients were divided into drug resistant group (48 cases) and sensitive group (74 cases) according to their sensitivity to platinum drugs. the clinical data and the levels of ANXA3 and HIF-1α in peripheral blood of the two groups were compared; Logistic regression model was used to analyze the influencing factors of platinum resistance; the receiver operating characteristic (ROC) curve was drawn to analyze the predictive efficacy of ANXA3 and HIF-1α in peripheral blood on platinum-based drug resistance.
There were no significant differences in sex composition, age, TNM stage and histological grade between the drug resistant group and sensitive group (P > 0.05). ANXA3 and HIF-1α levels in peripheral blood of the drug resistant group were significantly higher than those in the sensitive group (P < 0.05). The median progression free survival (PFS) of patients in the drug resistant group was 20.5 months (95%CI, 16.744 to 30.254), and the median PFS of patients in the sensitive group was 30.4 months (95%CI, 23.617 to 34.569). The median PFS of the drug resistant group was significantly shorter than that of the sensitive group (P < 0.05). ROC curve showed that the area under the curve (AUC) for predicting platinum resistance was 0.847 when 2.03 mg/L was the cut-off value; when HIF-1α was truncated at 189.57 pg/mL, the predicted AUC of platinum resistance was 0.722. The AUC of platinum resistance predicted by ANXA3 was significantly larger than that of HIF-1α(Z=2.201, P < 0.05). The AUC of ANXA3 combined with HIF-1α was 0.915, which was significantly larger than that of ANXA3 and HIF-1α alone (Z=2.150, 3.021, P < 0.05). Compared with ANXA3, ANXA3 combined with HIF-1α showed higher sensitivity in predicting platinum resistance; compared with HIF-1α, ANXA3 combined with HIF-1α had higher specificity in predicting platinum resistance.
High levels of ANXA3 and HIF-1α in peripheral blood are closely related to platinum-resistance in colorectal cancer. The combination of ANXA3 and HIF-1α shows high predictive efficacy in the determination of platinum-type drug resistance in colorectal cancer.
| [1] |
吴春晓, 顾凯, 龚杨明, 等. 2015年中国结直肠癌发病和死亡情况分析[J]. 中国癌症杂志, 2020, 30(4): 241-245. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202004001.htm
|
| [2] |
姚强, 金俊, 邓建良, 等. pN2Ⅲ期结直肠癌患者生存影响多因素分析[J]. 现代肿瘤医学, 2020, 28(5): 776-779. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202005018.htm
|
| [3] |
贾梦真, 黄岩杰, 杨晓青, 等. 运用基因调控技术探析膜联蛋白A2的病理作用[J]. 中国比较医学杂志, 2021, 31(1): 125-131. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGDX202101019.htm
|
| [4] |
张欢, 石文健, 刘永亮, 等. 垂体腺瘤患者缺氧诱导因子-1α与线粒体相关基因的相关性及肿瘤侵袭和复发的影响因素研究[J]. 实用心脑肺血管病杂志, 2021, 29(11): 58-62. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL202111012.htm
|
| [5] |
完家进, 朱芮, 杨联河. 外泌体与肿瘤化疗耐药研究进展[J]. 中华肿瘤防治杂志, 2019, 26(12): 891-896. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201912018.htm
|
| [6] |
肖刘牛, 朱丽, 陈颖铭, 等. Ⅱ期结直肠癌术后化疗临床预后危险因素的Meta分析[J]. 循证医学, 2019, 19(3): 167-177. https://www.cnki.com.cn/Article/CJFDTOTAL-YEBM201903013.htm
|
| [7] |
SHILKIN E S, BOLDINOVA E O, STOLYARENKO A D, et al. Translesion DNA synthesis and reinitiation of DNA synthesis in chemotherapy resistance[J]. Biochemistry (Mosc), 2020, 85(8): 869-882.
|
| [8] |
许学宗, 刘培培, 金博, 等. 血清ANXA2、PDCD5及COL4A3表达水平与肺癌患者临床病理特征及肿瘤转移的相关性[J]. 热带医学杂志, 2021, 21(2): 205-208, 120. https://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ202102019.htm
|
| [9] |
营晓梅, 陈亮, 吴晴晴, 等. ANXA1在甲状腺乳头状癌中的表达及临床意义[J]. 安徽医科大学学报, 2021, 56(12): 1987-1990. https://www.cnki.com.cn/Article/CJFDTOTAL-YIKE202112026.htm
|
| [10] |
谈燚, 孟海萍, 滕凤猛, 等. RNA干扰人膜联蛋白A3对胆囊癌细胞增殖的影响[J]. 中华肝胆外科杂志, 2010, 16(11): 853-856.
|
| [11] |
YANG L, LU P G, YANG X H, et al. Annexin A3, a calcium-dependent phospholipid-binding protein: implication in cancer[J]. Front Mol Biosci, 2021, 8: 716415.
|
| [12] |
JIN Y F, HUANG Y T, CHEN P F. ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin[J]. Eur Rev Med Pharmacol Sci, 2020, 24(7): 3741-3748.
|
| [13] |
WANG L M, LI X Q, REN Y H, et al. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells[J]. Cancer Sci, 2019, 110(5): 1609-1620.
|
| [14] |
谢婉新, 刘小雪, 陈立娜, 等. HIF-1α和ARNT在肿瘤转移及耐药中作用的研究进展[J]. 国际免疫学杂志, 2019, 42(3): 311-315.
|
| [15] |
孙艳丽, 陈飞, 陈武. 缺氧诱导因子-1α及Foxp3在结直肠癌组织中的表达及临床意义[J]. 中国实验诊断学, 2019, 23(5): 770-773. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD201905003.htm
|
| [16] |
孙佳, 肖海娟, 闫克敏, 等. 下调Annexin A3基因对结肠癌HCT116/L-OHP细胞生物学特性影响[J]. 中华肿瘤防治杂志, 2019, 26(11): 771-777. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201911004.htm
|
| [17] |
张韬, 罗自通, 蓝球生, 等. 肝再生磷酸酶-3上调缺氧诱导因子-1α亚基促进结肠癌细胞血管生成的研究[J]. 中华实验外科杂志, 2019, 36(5): 852-854.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: